We describe here a patient with metastatic urothelial carcinoma with EGFR exon 19 indel which progressed rapidly on standard therapies for urothelial carcinoma but demonstrated prolonged response to osimertinib, which is a third-generation tyrosine kinase inhibitor targeting EGFR. This evidence concerns the gene EGFR and urothelial carcinoma.